Company Overview - Protalix BioTherapeutics, Inc. is a biopharmaceutical company focused on the development, production, and commercialization of recombinant therapeutic proteins using its proprietary ProCellEx® plant cell-based protein expression system [4] - The company is notable for being the first to receive FDA approval for a protein produced through a plant cell-based suspension expression system [4] - Protalix has licensed worldwide development and commercialization rights for taliglucerase alfa, its first product, to Pfizer Inc., while retaining full rights in Brazil [4] Recent Developments - Protalix will present at the 2025 BIO CEO & Investor Conference on February 11, 2025, at 10:15 AM EST [1][2] - The company will provide a corporate overview and participate in one-on-one meetings with registered investors during the conference [2][3] - Protalix's second product, Elfabrio®, received approval from both the FDA and the European Medicines Agency in May 2023 [4] Product Pipeline - Protalix's development pipeline includes proprietary versions of recombinant therapeutic proteins targeting established pharmaceutical markets [5] - Key product candidates include PRX–115, a plant cell-expressed recombinant PEGylated uricase for uncontrolled gout, and PRX–119, a plant cell-expressed long-action DNase I for NETs-related diseases [5]

CHASKA, Minn., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate at the 2025 BIO CEO & Investor Conference. The conference will take place February 10-11, 2025, in New York, NY. Details regarding Lifecore’s participation are as follows: 2025 BIO CEO & Investor ConferenceDetails: Lifecore management, including Paul Josephs, chief executive o ...

Bio-Rad Laboratories, Inc.’s (BIO) solid momentum in the QX600 Droplet Digital PCR (ddPCR) platform is poised to help it grow in the upcoming quarters. The clinical diagnostics business sees increased demand for quality control products, boosting its growth. Furthermore, the company’s emphasis on international expansion bodes well.  Yet, a soft Biopharma segment and macro-driven pressures on Bio-Rad’s margins raise worries.In the past year, shares of this Zacks Rank #2 (Buy) company have soared 13.3% compar ...

MINNEAPOLIS, Jan. 8, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it will showcase its new ProPak™ GMP cytokines, alongside its portfolio of innovative products and solutions supporting cell and gene therapy development and manufacturing at Phacilitate's Advanced Therapies Week, taking place January 20-23 at the Kay Bailey Hutchison Convention Center in Dallas, Texas.Bio-Techne will feature its cell and gene therapy workflow reproducibility and scalability solutions, including ...

MINNEAPOLIS, Dec. 12, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities today announced a partnership with MedSanTek. Under the agreement, MedSanTek becomes the distributor of Bio-Techne's R&D Systems, Novus, Tocris, Protein Simple, Advanced Cell Diagnostics (ACD), and Asuragen brands across Turkey.Founded in the late 2000s, MedSanTek is a leading in vitro diagnosti ...

HOLMDEL, N.J., Dec. 02, 2024 (GLOBE NEWSWIRE) -- BIO-key® International, Inc. (NASDAQ: BKYI), an innovative provider of workforce and customer identity and access management (IAM) solutions featuring Identity-Bound Biometrics (IBB) for phoneless, tokenless, passwordless, and phish-resistant authentication experiences, today announced it has entered into an agreement with Fiber Food Systems, Inc. (“Fiber”), an innovative company with focus on global food security, developing innovation food-technology, and p ...

MINNEAPOLIS, Nov. 27, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer, will present at the Citi 2024 Global Healthcare Conference on Wednesday, December 4, 2024, at 3:15 p.m. EST. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.About Bio-TechneBio-Techne Corporation (NASDAQ: TECH) is a global life sciences ...

MINNEAPOLIS, Nov. 20, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities today announced a partnership with Leader Life Sciences. Under the agreement, Leader Life Sciences becomes a distributor of Bio-Techne's portfolio across the Gulf Cooperation Council (GCC) countries, which include Bahrain, Oman, Qatar, Saudi Arabia, and United Arab Emirates.Founded in 2020, Lead ...

MINNEAPOLIS, Nov. 18, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced a strategic partnership with ALZpath, Inc to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease. The collaboration leverages Bio-Techne's Ella™ fully automated, multiplexing immunoassay platform and ALZpath's proprietary pTau217 antibody to provide the Simple Plex Human Phospho-Tau (T217) ALZpath Assay. ALZpath The ALZpath pTau217 (phosphorylated Tau2 ...

HOLMDEL, N.J., Nov. 14, 2024 (GLOBE NEWSWIRE) -- BIO-key® International, Inc. (Nasdaq: BKYI), an innovative provider of workforce and customer Identity and Access Management (IAM) solutions featuring passwordless, phoneless and token-less Identity-Bound Biometric (IBB) authentication, announced results for its third quarter ended September 30, 2024 (Q3’24). BIO-key’s 2023 Q3 and nine month results were restated and filed with the Company’s 2023 Form 10-K and are reflected in this release. BIO-key will host ...